Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
OncoBayes
London, England, United Kingdomoncobayes.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
OncoBayes is a privately held, clinical-stage pharmaceutical company based in London, UK, focused on developing innovative oncology therapies to address major unmet medical needs. The company's lead program, OB-001, is a once-daily oral tablet designed as a highly selective inhibitor of key efflux pumps, P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP). By inhibiting these pumps, OB-001 aims to overcome antibody-drug conjugate (ADC) resistance and enhance the brain penetration of tyrosine kinase inhibitors (TKIs) like osimertinib. OncoBayes is preparing to advance OB-001 into clinical trials to generate proof-of-concept data in combination with standard-of-care cancer therapies.
- Therapeutic areas
- Oncology
- Modalities
- Small molecule
- Industry
- Biotech
Beyond the preview
Go deeper on OncoBayes.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OncoBayes.